Publication: Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
Issued Date
2004-09-01
Resource Type
ISSN
15254135
Other identifier(s)
2-s2.0-4444309788
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Acquired Immune Deficiency Syndromes. Vol.37, No.SUPPL. 1 (2004), 1160-1165
Suggested Citation
Punnee Pitisuttithum, Phillip W. Berman, Benjaluck Phonrat, Pravan Suntharasamai, Suwanee Raktham, La Ong Srisuwanvilai, Krit Hirunras, Dwip Kitayaporn, Jaranit Kaewkangwal, Sricharoen Migasena, Haynes W. Sheppard, Elizabeth Li, Marlene Chernow, Michael L. Peterson, Riri Shibata, William L. Heyward, Donald P. Francis Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. Journal of Acquired Immune Deficiency Syndromes. Vol.37, No.SUPPL. 1 (2004), 1160-1165. doi:10.1097/01.qai.0000136091.72955.4b Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/21578
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
Author(s)
Punnee Pitisuttithum
Phillip W. Berman
Benjaluck Phonrat
Pravan Suntharasamai
Suwanee Raktham
La Ong Srisuwanvilai
Krit Hirunras
Dwip Kitayaporn
Jaranit Kaewkangwal
Sricharoen Migasena
Haynes W. Sheppard
Elizabeth Li
Marlene Chernow
Michael L. Peterson
Riri Shibata
William L. Heyward
Donald P. Francis
Phillip W. Berman
Benjaluck Phonrat
Pravan Suntharasamai
Suwanee Raktham
La Ong Srisuwanvilai
Krit Hirunras
Dwip Kitayaporn
Jaranit Kaewkangwal
Sricharoen Migasena
Haynes W. Sheppard
Elizabeth Li
Marlene Chernow
Michael L. Peterson
Riri Shibata
William L. Heyward
Donald P. Francis
Abstract
A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.